Table 1.
Characteristics of the cohort
| Characteristics | All (n = 2798) |
Women (n = 1552) |
Men (n = 1246) |
|---|---|---|---|
| Subject characteristics at baseline | |||
| Mean age, years (SD) | 65.8 (14.8) | 65.9 (16.3) | 65.6 (12.7) |
| Mean BMI, kg/m2 (SD) | 30.2 (7.7) | 30.4 (8.5) | 29.9 (6.7) |
| Current smoker, % | 8.9 | 8.9 | 9.0 |
| Hyperlipidemia1, % | 24.3 | 20.3 | 29.4 |
| Prevalent CVD, % | 23.7 | 21.1 | 27.1 |
| Cancer2, % | 23.3 | 23.6 | 22.9 |
| Recent hospitalization, <30 days | 23.3 | 24.6 | 21.7 |
| Oral estrogen hormone therapy, % | 5.9 | 10.6 | 0.0 |
| Baseline lipid-lowering treatment | |||
| Statin, % | 22.1 | 19.5 | 25.4 |
| Simvastatin, % | 42.8 | 43.7 | 42.0 |
| Lovastatin, % | 48.5 | 49.0 | 48.0 |
| Other statin, % | 8.7 | 7.3 | 10.1 |
| Non-statin, % | 1.3 | 0.8 | 1.8 |
| Event characteristics | |||
| Incident VT event | |||
| PE, % | 52.9 | 54.5 | 50.9 |
| Idiopathic3, % | 50.9 | 43.9 | 59.6 |
| Death within 30 days4, % | 7.3 | 7.6 | 6.9 |
| Anticoagulation treatment5 | 96.7 | 96.9 | 96.4 |
SD = standard deviation; GHC = Group Health Cooperative; BMI = body mass index; CVD = cardiovascular disease including a history of myocardial infarction, unstable angina, angina pectoris, cardiac revascularization procedure, ischemic and hemorrhagic stroke, peripheral vascular disease, and carotid endarterectomy; VT = venous thrombosis; PE = pulmonary embolism
Defined as hyperlipidemic if taking a lipid-lowering medication at index and with a physician diagnosis of hyperlipidemia.
Defined as cancer diagnosis or treatment in the 2 years prior to index.
Defined as no cancer at event or in the 2 years prior; no inpatient surgery, hospitalization or fracture in the 30 days prior to event; not pregnant at the time of the event or in the 1 year prior; not currently using oral estrogen hormone therapy; not currently using oral contraceptives.
Defined as death in <31 days following an incident VT.
Defined as treatment prevalent at the time of incident VT event or started within 30 days.